H.R. 3974
Referred to CommitteePrescription Drug Monitoring Act of 2019
Latest Action
Referred to the Subcommittee on Health.
7/26/2019 • House
Summary
Prescription Drug Monitoring Act of 2019
This bill expands the notification and reporting requirements with respect to potentially addictive prescription drugs for states receiving funds for a Prescription Drug Monitoring Program (PDMP). Dispensers of these drugs, which includes substances listed in schedule II, III, or IV of the Controlled Substances Act, must consult with the PDMP before starting treatment involving such drugs and report each prescription of such drugs to the PDMP within 24 hours.
The state agency administering a PDMP must analyze reported data for patterns of controlled substance misuse or abuse and provide certain information to law enforcement, the public, and other states.
Introduced in House • 7/25/2019
Topics & Subjects
Congressional Votes (0)
No recorded votes yet
Roll call votes will appear here as the bill moves through Congress
Related Federal Spending
Sponsor & Cosponsors (8)
Party Breakdown
Sponsor
Cosponsors (7)
Bill Journey
Originated in the House
Introduced
July 25, 2019
Referred to the House Committee on Energy and Commerce.
Committee Review
Floor Debate
Passed Chamber
Other Chamber
President
Enacted into Law